iStat Biomedical Co., Ltd. - Epigene

iStat, Epigene, Epigenebio, Cervical cancer test, Oral cancer test, Cancer methylation test, Epigenetic IVD assay, Non-invasive early cancer detection, DNA Methylatoin, 日祥, 甲基化基因檢測, 癌症基因檢測

iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.

Latest News - #Last News

iStat Biomedical attended CSCCP 2017 in China

          iStat Biomedical Co., Ltd. attended Chinese Society for Colposcopy and Cervical Pathology (CSCCP) 2017 Conference in Beijing, China, from May 19th to 21th, which is the largest conference on gynecology and gynecologic oncology in China. This conference is dedic ...

iStat Biomedical First Awarded the PTRD Award from TFDA

  iStat Biomedical First awarded the Pharmaceutical Technology Research and Development Award from TFDA       The“Pharmaceutical Technology Research and Development Award (PTRD)”given by the Taiwan Food and Drug Administration (TFDA) recognizes and encourages th ...

1st prize at the 2nd international Gynecologic Oncology Forum

iStat Biomedical Co. Ltd will receive the 1st prize at the 2nd (2014) International Gynecologic Oncology Forum (Hunan, China) The forum is hold by the Cervical Cancer Prevention Expert Committee of Hunan Female Physicians Association and the Hunan Cancer Hospital on April 25, 2014 at Changsha, Hu ...

Invited to join the 3rd seminar on Cross-Strait Cooperation

Dr. Chi-Fang Chang, CEO of the iStat Biomedical Co. Ltd is invited to join the 3rd seminar on Cross-Strait Cooperation in Research and Development of Pharmaceuticals Dr. Chi-Fang Chang, CEO of the iStat Biomedical Co. Ltd is invited to share the experience of the discovery and clinical trial of c ...

Attend the 8th International China Pharmaceutical R&D Summit

Dr. Chi-Fang Chang, CEO of the iStat Biomedical Co. Ltd is invited to attend the 8th International China Pharmaceutical R&D Summit The China Pharmaceutical R&D Summit is to bring together leaders from across East and West, pharma and biotech, discovery and clinical to discuss the future o ...

Emerging Technologies for 21st Century Diagnostics

iStat Biomedical Co. Ltd will attend the 45th Oak Ridge Conference: Emerging Technologies for 21st Century Diagnostics Oak Ridge Conferencefor the tradition of being the premier venue for emerging technologies that will shape the future of testing in clinical diagnostic labs. We will issue the r ...

iStat will cooperate with DNA Research Centre(M) Sdn Bhd.

iStat Biomedical Co. Ltd will cooperate with DNA Research Centre(M) Sdn Bhd. iStat Biomedical Co. Ltd will cooperate with DNA Research Centre(M) Sdn Bhd (DNA Lab, Malaysia) in order to build the alliance for the Malaysia and Southeast Asia market. The burden of cervical cancer in Southeast Asia ...
iStat- Epigenetic IVD assay for cancer DNA methylation biomarkers. iStat is a Taiwan-based biotechnology company specialized in the development and manufacturing of high quality gene methylation assay products for the early detection of cervical, oral, and bladder cancers. The company provides innovative IVD products for use in the clinical laboratories and solutions for medication managements. The company is actively seeking distributors in Europe, Middle East, and Latin America, and is discussing licensing potentials with some of the global companies.
en